Advertisement

Picture EBD Group BIO-Europe 2024 Stockholm from 14 Sep 650x100px
Organisation › Details

BioNTech (Group)

BioNTech SE is Europe’s largest privately-held biopharmaceutical company pioneering the development of precision immunotherapies for individualized treatment of cancer and prevention of infectious diseases. The company combines all building blocks for more precise and individualized immunotherapies under one roof – from diagnostics and drug development to manufacturing. Its cutting-edge technologies range from individualized mRNA-based product candidates through innovative chimeric antigen receptors and T-cell receptor-based compounds to novel checkpoint immunomodulators and small molecules. BioNTech’s product development approach has been validated by seven corporate partnerships with, in chronological order, Genmab, Eli Lilly and Company, Sanofi, Bayer Animal Health, Genentech, a member of the Roche Group, Genevant and Pfizer, and its scientific approach through over 60 peer-reviewed scientific publications. Founded in 2008, BioNTech’s financial shareholders include the Struengmann Family Office as its majority shareholder, Fidelity Management & Research Company, Invus, Janus Henderson Investors, MIG Fonds, Redmile Group, Salvia and several European family offices. *

 

Period Start 2008-01-01 established
  Predecessor University of Mainz (Johannes Gutenberg University)
Products Industry cancer immunotherapy (immuno-oncology, I-O)
  Industry 2 cancer test
Persons Person Sahin, Ugur (BioNTech 201207 Managing Director BioNTech + Ribological GmbH)
  Person 2 Holstein, Jens (BioNTech 202107– CFO before MorphoSys 201105–202012 CFO before Fresenius Kabi)
     
Region Region Mainz
  Country Germany
  Street 12 An der Goldgrube
  City 55131 Mainz
  Tel +49-6131-9084-0
    Address record changed: 2024-01-05
     
Basic data Employees G: 5,001 to 10,000 (2023-12-31)
  Currency EUR
  Annual sales 3,819,000,000 (revenues, total, consolidated (2023) 2023-12-31)
  Profit 930,300,000 (2023-12-31)
  Cash 11,663,700,000 (2023-03-31)
     
    * Document for »About Section«: BioNTech SE. (5/8/19). "Press Release: BioNTech Acquires MabVax Therapeutics’ Antibody Assets to Expand Portfolio". Mainz.
     
   
Record changed: 2024-03-22

Advertisement

Picture EBD Group Biotech Showcase 2025 San Francisco BTS25 650x200px

More documents for BioNTech (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

Picture EBD Group BIO-Europe 2024 Stockholm from 14 Sep 650x300px




» top